MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Home・Akciju saraksts・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Slēgts

4.12 4.04

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.09

Max

4.14

Galvenie mērījumi
By Trading Economics
Ienākumi	466K -27M
Pārdošana	2M 15M
Peļņas marža	-178.834
Darbinieki	141
EBITDA	-2M -29M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+255.21% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	345K 229M
Iepriekšējā atvēršanas cena	0.08
Iepriekšējā slēgšanas cena	4.12

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

3.17 / 3.4644 Atbalsts un pretestība

Voyager Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 19. apr. 23:48 UTC

Galvenie ziņu notikumi

Crude Oil, Refined Product Prices Moving Higher Amid Renewed Tensions in Strait of Hormuz -- OPIS

2026. g. 19. apr. 23:36 UTC

Galvenie ziņu notikumi

NAB Raises Provisions as Australian Banks Face Iran Risks -- Update

2026. g. 19. apr. 22:47 UTC

Galvenie ziņu notikumi

National Australia Bank Adds $215 Million in Iran-Driven Credit Provisions

2026. g. 19. apr. 21:14 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

2026. g. 19. apr. 21:14 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

2026. g. 19. apr. 23:49 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold, Silver Decline Amid Renewed Inflation Concerns -- Market Talk

2026. g. 19. apr. 23:46 UTC

Tirgus saruna

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

2026. g. 19. apr. 23:38 UTC

Galvenie ziņu notikumi

U.A.E. Asks U.S. About a Wartime Financial Lifeline -- Update

2026. g. 19. apr. 23:36 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Climbs on Renewed Tensions Over Strait of Hormuz -- Market Talk

2026. g. 19. apr. 23:12 UTC

Galvenie ziņu notikumi

Spot Gold Falls 1.2%, Spot Silver Drops 1.6% on Renewed Middle East Tensions

2026. g. 19. apr. 23:10 UTC

Galvenie ziņu notikumi

Front-Month Brent Crude Oil Futures Rise 5.8% to $95.64 per Barrel

2026. g. 19. apr. 23:09 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Climb 7.2% to $89.86 per Barrel

2026. g. 19. apr. 23:08 UTC

Galvenie ziņu notikumi

Front-Month Crude Oil Futures Climb on Renewed Tensions Over Strait of Hormuz

2026. g. 19. apr. 21:20 UTC

Iegādes, apvienošanās, pārņemšana

Eli Lilly Nears Deal for Cancer Biotech -- WSJ

2026. g. 19. apr. 21:20 UTC

Iegādes, apvienošanās, pārņemšana

Announcement Could Come As Soon As Monday, Sources Say -- WSJ

2026. g. 19. apr. 21:20 UTC

Iegādes, apvienošanās, pārņemšana

Deal Expected to Be Worth Over $2B Plus Additional Milestones, Sources Say -- WSJ

2026. g. 19. apr. 21:20 UTC

Iegādes, apvienošanās, pārņemšana

Eli Lilly Nears Deal for Kelonia Therapeutics, Sources Say -- WSJ

2026. g. 19. apr. 20:03 UTC

Galvenie ziņu notikumi

U.A.E. Central Bank Governor Khaled Mohamed Balama Raised Swap Idea With Treasury Secretary Scott Bessent in Washington -- WSJ

2026. g. 19. apr. 20:03 UTC

Galvenie ziņu notikumi

Emiratis Portrayed Swap Proposal as Precautionary and Preliminary in Case Iran War Drags On -- WSJ

2026. g. 19. apr. 20:03 UTC

Galvenie ziņu notikumi

The U.A.E. Has Opened Talks with U.S. for Currency Swap -- WSJ

2026. g. 19. apr. 20:03 UTC

Galvenie ziņu notikumi

U.A.E. Asks U.S. for a Wartime Financial Lifeline -- WSJ

2026. g. 18. apr. 01:00 UTC

Galvenie ziņu notikumi

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

2026. g. 17. apr. 22:58 UTC

Peļņas

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

2026. g. 17. apr. 21:32 UTC

Tirgus saruna

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

2026. g. 17. apr. 21:22 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 17. apr. 21:22 UTC

Tirgus saruna

Moody's Downgrades Belgium to A1 -- Market Talk

2026. g. 17. apr. 20:52 UTC

Peļņas

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

2026. g. 17. apr. 20:50 UTC

Tirgus saruna

Peļņas

Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2026. g. 17. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 17. apr. 20:29 UTC

Peļņas

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Voyager Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

255.21% augšup

Prognoze 12 mēnešiem

Vidējais 14.67 USD 255.21%

Augstākais 25 USD

Zemākais 8 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

3.17 / 3.4644Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.